CD123 Redirected T Cells for AML in Pediatric Subjects

University of Pennsylvania

Status and phase

Terminated

Phase 1

Conditions

Acute Myeloid Leukemia, in Relapse

Acute Myeloid Leukemia, Refractory

Acute Myeloid Leukemia, Pediatric

Treatments

Biological: CART123 cells; cyclophosphamide; fludarabine

Study type

Interventional

Funder types

Other

Identifiers

NCT04678336

834675 (19CT011)

Details and patient eligibility

About

Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia (AML).

Full description

This is a Phase 1 study designed to evaluate the safety, feasibility, and preliminary efficacy of CART123 cells in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia (AML). The study was originally designed to evaluate these primary endpoints at a single CART123 dose level (2x106 CART123 cells/kg). This dose level was selected based on experience in an adult trial using this investigational product in relapsed/refractory AML patients (NCT03766126).

As of Protocol Amendment V6, the study design has been converted into a 3+3 dose escalation design in order to further explore the safety of CART123 cells in the target disease population, and determine a maximum tolerated dose (MTD). The initial dose level (2x106 CART123 cells/kg) will be retrospectively identified as Dose Level 1 (DL1), and up to two new dose levels of CART123 cells will now be evaluated as follows:

Dose Level 1 (DL1): 2x106 CART123 cells/kg

o <DL1 Fully Enrolled as of Protocol Amendment V6>
Dose Level 2 (DL2): 5x106 CART123 cells/kg
Dose Level 3 (DL3): 1x107 CART123 cells/kg

Dose Level 1 (DL1) was fully evaluated as of Protocol Amendment V6. Dose Level 2 (DL2) and Dose Level 3 (DL3) will be evaluated as follows:

Dose Level 2 (N = 3-6):
- If 1 DLT/3 subjects occurs, 3 additional DLT-evaluable subjects will enrolled at this dose level.
- If 0 DLT/3 subjects or 1 DLT/6 subjects occur, DL2 safety data will be submitted to the DSMB for review. DSMB approval must be received in order to advance to Dose Level 3 (DL3).
- If 2 DLTs occur at any time, additional enrollment on this study will be paused to allow for further investigation.
Dose Level 3 (N = 3-6):
- If 1 DLT/3 subjects occurs, 3 additional DLT-evaluable subjects will be enrolled at this dose level.
- If 0 DLT/3 subjects, 3 additional DLT-evaluable subjects will be enrolled at this dose level to further evaluate safety and allow for MTD determination.
- If 2 DLTs occur at any time, enrollment at this dose level will be stopped. If fewer than 6 evaluable subjects were infused at DL2, additional subjects will be enrolled at that dose level to reach a minimum of 6 DLT-evaluable subjects for MTD determination.

The DLT observation period is 28 days post-CART123 cell infusion (Day 0). In order to allow for appropriate monitoring/assessment of toxicities, study treatment in the 1st and 2nd subjects at each dose level must be staggered by at least 28 days, such that the next subject will not receive treatment (lymphodepleting chemotherapy plus CART123 cells) until the previous subject has completed their Day 28 safety follow-up visit. If there are no emergent safety concerns identified in the first subject infused, study treatment for subsequent subjects at that same dose level do not need to be staggered and may occur sequentially without additional staggering requirements. Formal DLT evaluations will be performed after the 3rd evaluable subject at each dose level reaches the Day 28 safety follow-up visit. These formal DLT evaluations will allow for a formal decision regarding dose level progression, expansion, or dose de-escalation. Formal DLT evaluations will be determined by the Clinical PI and Sponsor Medical Director in accordance with the definition in the protocol. The MTD is defined as the highest dose at which 0 or 1 DLT occurs in 6 evaluable subjects.

It is recommended that subjects with marrow aplasia at Day 28+/-5 undergo an allogeneic hematopoietic cell transplantation (alloHCT) as a rescue strategy. If required, this procedure will be performed as part of routine care, outside of the scope of this research study; however, subjects will continue to be followed onstudy. All subjects must, therefore, have a previously identified stem cell donor as part of their eligibility to participate in this study. All subjects will be followed monthly for up to 6 months after the CART123 cell infusion (Day 0). Thereafter, subjects will be transitioned into LTFU for up to 15 years post infusion.

Enrollment

12 patients

Sex

All

Ages

1 to 29 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male and female patients ≥ 1 and ≤ 29 years of age at time of consent.
AML in second or greater relapse, post-transplant relapse, or chemotherapy-refractory disease. Specifically:
1. Second or greater relapse defined as flow cytometric confirmation of myeloid leukemia of at least 0.1% after second documented complete remission; OR
2. Any detectable disease post-allogeneic transplant with flow cytometric confirmation (MRD) of myeloid leukemia of at least 0.1% (as confirmed by Hematologics); OR
3. Refractory disease, defined as persistent bone marrow involvement with >5% blasts after two courses of induction chemotherapy for patients at initial presentation or >5% bone marrow blasts after one course of re-induction chemotherapy for patients who have relapsed after previously achieving a CR.
Subjects must have a suitable stem cell donor identified with projected ability to proceed to transplant within 6-8 weeks of CART123 infusion.
Adequate organ function defined as:
1. A serum creatinine based on age/gender
2. Adequate liver function
i. ALT ≤ 5 x ULN

ii. Total bilirubin ≤ 3 x ULN

iii. ALT and/or bilirubin results that exceed this range are acceptable if, in the opinion of the physician-investigator (or as confirmed by liver biopsy), the abnormalities are directly related to AML infiltration of the liver.

c. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and < Grade 3 hypoxia; DLCO ≥ 40% (corrected for anemia) if PFTs are clinically appropriate as determined by the treating investigator

d. Left Ventricular Shortening Fraction (LVSF) ≥ 28% or Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO, or adequate ventricular function documented by a scan or a cardiologist. In cases where quantitative assessment of LVSF/LVEF is not possible, a statement by the cardiologist that the ECHO shows qualitatively normal ventricular function will suffice.
Adequate performance status defined as Lansky or Karnofsky score ≥ 50
Signed informed consent must be obtained.
No contraindications for leukapheresis (unless apheresis product previously acquired).
Subjects of reproductive potential must agree to use acceptable birth control methods.

Exclusion criteria

Pregnant or lactating (nursing) women.
Patients with relapsed AML with t(15:17).
Patients < 6 months from alloHSCT.
HIV infection.
Active hepatitis B or hepatitis C infection.
Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy
Patients requiring chronic treatment with systemic steroids or immunosuppressant medications. Low-dose physiologic replacement therapy with corticosteroids, topical steroids and inhaled steroids are acceptable. For additional details regarding use of steroids and immunosuppressant medications (including washout requirements prior to CAR T cell administration).
Any uncontrolled active medical disorder that would preclude participation as outlined.
Uncontrolled active infection
Subjects with CNS3 disease that is progressive on therapy or with CNS parenchymal lesions that may increase the risk of CNS toxicity. Subjects with adequately treated CNS leukemia are eligible.
Known history of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).
Patients with any prior history of myeloproliferative neoplasm.
Patients with somatic JAK2 V617F mutation by PCR or next generation sequencing.